X hits on this document

Word document

I.EXECUTIVE ORDERS - page 173 / 359

1723 views

0 shares

0 downloads

0 comments

173 / 359

b.the form or forms in which the substance is received, imported, or manufactured by the licensee (e.g., powder, granulation, tablet, capsule, or solution) and the concentration of the substance in such form (e.g., C.P., U.S.P., N.F., 10-milligram tablet or 10-milligram concentration per milliliter);
c.the total number of the forms received, imported or manufactured (e.g., 100 tablets, 30 1-milliliter vials, or 10 grams of powder), including the date and quantity of each receipt, importation, or manufacture and the name, address, and DEA registration number, if any, of the person from whom the substance was received;
d.the quantity distributed, exported, or destroyed in any manner by the licensee (except quantities used in chemical analysis or other laboratory work), including the date and manner of distribution, exportation, or destruction, and the name, address, and DEA registration number, if any, of each person to whom the substance was distributed or exported.
2.Records of controlled substances used in chemical analysis or other laboratory work are not required.
3.Records relating to known or suspected controlled substances received as evidentiary material for analysis are not required by this Section.

D.Records for Narcotic Treatment Programs

1.Each person authorized by federal and state law to maintain and/or detoxify controlled substance users in a narcotic treatment program shall maintain records with the following information for each narcotic controlled substance:
a.name of substance;
b.strength of substance;
c.dosage form;
d.date dispensed;
e.adequate identification of patient (consumer);
f.amount consumed;
g.amount and dosage form taken home by patient; and
h.dispenser's initials.
2.The records required by this Section will be maintained in a dispensing log at the narcotic treatment program site and will be maintained in compliance with Subsection B of this Section.
3.All sites which compound a bulk narcotic solution from bulk narcotic powder to liquid for on-site use shall keep a separate batch record of the compounding.
4.Records of identity, diagnosis, prognosis, or treatment of any patients which are maintained in connection with the performance of a narcotic treatment program shall be confidential, except that such records may be disclosed for purposes and under the circumstances authorized by law.

E.Records for Compounders for Narcotic Treatment Programs. Each person authorized to compound narcotic drugs for off-site use in a narcotic treatment program shall maintain records which include the following information:

1.for each narcotic controlled substance in bulk form to be used in, or capable of use in, or being used in, the compounding of the same or other non-controlled substances in finished form:
a.the name of the substance;
b.the quantity compounded in bulk form by the licensee, including the date, quantity and batch or other identifying number of each batch compounded;
c.the quantity received from other persons, including the date and quantity of each receipt and the name, address and registration number of the other person from whom the substance was received;
d.the quantity imported directly by the licensee (under a registration as an importer) for use in compounding by him, including the date, quantity and import permit or declaration number of each importation;
e.the quantity used to compound the same substance in finished form, including:
i.the date and batch or other identifying number of each compounding;
ii.the quantity used in the compound;
iii.the finished form (e.g., 10-milligram tablets or 10-milligram concentration per fluid ounce or milliliter);
iv.the number of units of finished form compounded;
v.the quantity used in quality control;
vi.the quantity lost during compounding and the causes therefore, if known;
vii.the total quantity of the substance contained in the finished form;
viii.the theoretical and actual yields; and
ix.such other information as is necessary to account for all controlled substances used in the compounding process;
f.the quantity used to manufacture other controlled and non-controlled substances; including the name of each substance manufactured and the information required in Clause B.1.a.v of this Section;
g.the quantity distributed in bulk form to other programs, including the date and quantity of each distribution and the name, address and registration number of each program to whom a distribution was made;
h.the quantity exported directly by the licensee (under a registration as an exporter), including the date, quantity, and export permit or declaration number of each exploration; and
i.the quantity disposed of by destruction, including the reason, date and manner of destruction;
2.tor each narcotic controlled substance in finished form:
a.the name of the substance;
b.each finished form (e.g., 10-milligram tablet or 10 milligram concentration per fluid ounce or milliliter) and the number of units or volume or finished form in each commercial container (e.g., 100-tablet bottle or 3-milliliter vial);
c.the number of containers of each such commercial finished form compounded from bulk form by the licensee, including the information required pursuant to Clause B.1.a.v of this Section;
d.the number of units of finished forms and/or commercial containers received from other persons, including the date of and number of units and/or commercial containers in each receipt and the name, address and registration number of the person from whom the units were received;

Louisiana Register   Vol. 34, No. 10   October 20, 2008

Document info
Document views1723
Page views1726
Page last viewedFri Dec 09 13:40:24 UTC 2016
Pages359
Paragraphs18243
Words293762

Comments